苦参碱、氧化苦参碱联合应用对ECV304活性及能量代谢影响  

Effect of Matrine and Oxymatrine on Proliferation and Energy Metabolism of ECV304

作　　者：王淑静[1] 孙微微[1] 张家宁[1] 赵健凯[1] 任爽[1] 张文君[1] 

机构地区：[1]哈尔滨商业大学药学院,哈尔滨150076

出　　处：《天然产物研究与开发》2017年第5期741-746,共6页Natural Product Research and Development

基　　金：哈尔滨市科技创新人才研究专项基金(2016RQQXJ095);2016年哈尔滨商业大学研究团队支持项目(2016TD009)

摘　　要：为探讨苦参碱和氧化苦参碱联合应用对人脐静脉内皮ECV304细胞活性及能量代谢影响,采用排列组合法确定苦参碱和氧化苦参碱联合用药的浓度配比,生长曲线法检测细胞增殖抑制作用,HE染色、透射电镜观察细胞形态变化,试剂盒测定糖代谢中相关酶活力和代谢产物含量。结果显示,氧化苦参碱1200μg/m L和苦参碱600μg/m L联合作用效果较好,联合应用对ECV304增殖抑制和形态改变较氧化苦参碱、苦参碱明显增强,可明显降低有氧氧化中的琥珀酸脱氢酶活力及ATP含量,对糖酵解的己糖激酶、丙酮酸激酶及乳酸影响较小。研究表明氧化苦参碱、苦参碱联合应用明显干扰ECV304细胞氧化磷酸化有关酶活性,减少ATP生成,抑制ECV304细胞增殖,实现抗肿瘤血管生成的间接抗肿瘤作用。The aim of this study was to investigate the effect of matrine and oxymatrine combination on the activity and energy metabolism of human umbilical vein endothelial cells （ ECV304 ）. The method of permutation and combination was used to determine the best ratio of matrine and oxymatrine concentration. The cell growth curves were used to describe the effect of matrine and oxymatrine combination on cell proliferation. The morphological changes of ECV304 cells were determined by HE staining and transmission electron microscopy. The enzymatic activity and metabolite quantity of the metabolite related enzymes in ECV304 cells was also measured. Results showed that matrine at 1200 μg/mL and oxymatrine at 600 μg/mL combination had a better effect. The proliferation of ECV304 cells was significantly inhibited by the combined usage of matrine and oxymatrine and the cells morphology were also changed significantly as compared with control group and matrine/oxymatrine group. The combination usage of these two drugs did not affect HK activity, PK activity and lactate metabolism in glycolysis, but can significantly reduce SDH activity and ATP level in oxidation process. Combined usage of matrine and oxymatrine had an indirectly antitumor effect in ECV304 cells by inhibiting cell proliferation and tumor angiogenesis.

关 键 词：苦参碱 氧化苦参碱 人脐静脉内皮ECV304细胞 能量代谢 细胞增殖 

分 类 号：R73-354[医药卫生—肿瘤]